While the drug has shown to be effective, Gotte is cautioning against jumping to conclusions on how the drug will work in the general population until clinical trials, which have been fast-tracked by the World Health Organization, have concluded. "The best news is that most of our patients have already been discharged, which is great", Mullane says in the video.
Earlier, another trial in China testing the drug in those with severe COVID-19 was terminated because no eligible patients could be enrolled. So, in that realm, overall our patients have done very well. Shares of Boeing Co. surged after-hours after saying it will resume commercial plane production at a plant near Seattle next week. It said majority have been discharged and two patients died. Gilead said earlier this week that a compassionate drug use programme sponsored by the company found that out of 53 patients with severe Covid-19 infections, clinical improvement was observed in 36.
Mullane said she was cautious about the results, partly because there was no placebo group, but that patients had come off ventilators a day after starting treatment and had left hospital after six days. "We have very few that went out to 10 days, maybe three", she said.
Indonesia reports its biggest daily jump in coronavirus deaths
In one paper, researchers found nearly half (46 per cent) of all patients hospitalised with coronavirus were aged 65 or over. Most of the patients hospitalized are 65 or older, as are most of the reported deaths, according to the state.
GlobalData suggested recently that remdesivir's antiviral mechanism means it "has the potential to decrease viral load in less-severe patients" with COVID-19, but that in those who are more critically ill "the disease's inflammatory impact becomes the more significant factor to address".
So far the only data on the drug in this setting comes from an open-label study of the drug in a varied group of compassionate-use patients, which pointed to a benefit but was hard to interpret.
"The big question is whether it's going to be enough to help the economy "re-open" more quickly than people are thinking right now", he explained. "Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for COVID-19". "Still, no other clinical data from the Gilead studies have been released to date, and excitement is high". "We are grateful for all of the efforts of investigators and patients participating in our studies and look forward to sharing the results from the complete dataset".